Telomir completes TELI acquisition, issues 34.39M shares

Telomir Pharmaceuticals, Inc. completed its acquisition of TELI Pharmaceuticals, Inc. on April 22, 2026, following shareholder approval on March 23, 2026. The transaction involved issuing 34,389,710 restricted shares of Telomir's common stock to TELI's former shareholders. This acquisition consolidates the global rights of Telomir-1 (Telomir-Zn) under Telomir, eliminating prior geographic fragmentation and granting full control over its development and commercialization. Additionally, Bayshore Trust contributed $1 million at closing and holds an option to invest up to $4 million more upon the achievement of specific clinical milestones for Telomir-1.